Venture Capital Investors

Alta Partners

Alta Partners is a VC investing group investing in select companies.

Venture Investor Overview

Venture Investor
Alta Partners
Status
Active
Investor Type
Venture Capital
Activity Level
238 transactions
Funds Raised
At least $630 million
Industry Focus
Biopharmaceutical
Healthcare IT
Healthcare Services
Life Sciences

Contact Information

Contact
Guy Nohra
Title
Managing Director
Mailing Address
1 Embarcadero Center 3700
San Francisco, CA 94111
USA
Phone
(415) 362-4022
Website
www.altapartners.com
Email Address
[email protected]

Background Information

Overview
Alta is committed to building successful businesses through deep collaborative partnerships with outstanding entrepreneurs. We invest only in those areas where we have specific domain expertise. We are long-term investors and believe that it is critical to be a value-added investor by actively working with portfolio company management teams to help build market-leading companies.
Profile
Alta Partners LinkedIn Company Profile
Social Media
Alta Partners Company Twitter Account
Company News
Alta Partners News
Facebook
Alta Partners on Facebook
YouTube
Alta Partners on YouTube
Last Transaction
10/23/2024

Transaction History

Our records indicate that Alta Partners invested in the VC transactions listed below. Dollar amounts are for the entire raise, which may include other investors.

Company
Date
Amount
Be Biopharma
10/23/2024
$82,000,000
eGenesis
9/4/2024
$191,000,000
Progentos Therapeutics
5/20/2024
$65,000,000
Edgewood Oncology
3/25/2024
$20,000,000
Harbor Health
1/11/2024
$95,500,000
Lassen Therapeutics
12/20/2023
$85,000,000
MBrace Therapeutics
11/14/2023
$85,000,000
Free Market Health
11/1/2023
$20,000,000
BetterVet
11/16/2022
$40,000,000
Novome Biotechnologies
9/13/2022
$43,500,000
Everside Health
7/25/2022
$164,000,000
DEM BioPharma
6/23/2022
$70,000,000
Kelonia Therapeutics
4/28/2022
$50,000,000
Be Biopharma
4/14/2022
$130,000,000
Transcarent
1/19/2022
$200,000,000
ImmuneID
6/24/2021
$50,000,000
Transcarent
6/11/2021
$58,000,000
Tyra Biosciences
4/2/2021
$106,000,000
DispatchHealth
3/5/2021
$200,000,000
eGenesis
3/3/2021
$125,000,000
PatientsLikeMe
2/11/2021
$26,000,000
BridgeHealth
10/26/2020
$40,000,000
Be Biopharma
10/23/2020
$52,000,000
Tyra Biosciences
1/14/2020
$50,000,000
Novome Biotechnologies
1/8/2020
$33,000,000
eGenesis
11/8/2019
$100,000,000
DispatchHealth
5/9/2019
$33,000,000
CuraSen Therapeutics
10/18/2018
$54,500,000
Paladina Health
8/27/2018
$165,000,000
Sutro Biopharma
7/30/2018
$85,400,000
Allakos
12/14/2017
$100,000,000
Vir Biotechnology
10/18/2017
$500,000,000
DispatchHealth
9/25/2017
$30,800,000
eGenesis
3/17/2017
$38,000,000
VertiFlex
3/9/2017
$40,000,000
Allakos
3/31/2016
$8,401,000
Reach Analytics
1/13/2016
Unknown
Allakos
9/30/2014
$10,000,000
Virobay
7/17/2014
$8,000,000
Lumena Pharmaceuticals
3/11/2014
$45,000,000
ZS Pharma
3/6/2014
$55,000,000
Neothetics
2/12/2014
$8,000,000
Achaogen
12/31/2013
$10,000,000
CymaBay Therapeutics
12/31/2013
$3,321,000
SCYNEXIS
12/31/2013
$2,500,000
Sutro Biopharma
12/11/2013
$26,000,000
Zafgen
12/4/2013
$45,000,000
Immune Design
10/30/2013
$49,000,000
ZS Pharma
9/30/2013
$15,100,000
Cara Therapeutics
9/30/2013
$603,000
aTyr Pharma
7/29/2013
$49,000,000
AGTC
6/30/2013
$9,621,000
Kite Pharma
5/15/2013
$20,000,000
Lumena Pharmaceuticals
5/8/2013
$8,000,000
Esperion Therapeutics
4/25/2013
$33,000,000
Immune Design
12/31/2012
$10,625,000
Neothetics
12/20/2012
$20,600,000
Allakos
12/18/2012
$32,000,000
Zafgen
12/4/2012
$21,000,000
AGTC
11/21/2012
$37,500,000
ZS Pharma
10/26/2012
$46,000,000
Lumena Pharmaceuticals
9/30/2012
$10,000,000
Ceregene
6/30/2012
$7,655,000
USGI Medical
6/30/2012
$16,548,000
Sutro Biopharma
5/8/2012
$16,500,000
VertiFlex
3/31/2012
$8,000,000
SCYNEXIS
3/31/2012
$222,000
Trevena
12/31/2011
$10,000,000
PneumRx
12/31/2011
$8,584,000
SCYNEXIS
12/31/2011
$5,503,200
Immune Design
9/30/2011
$10,625,000
Trevena
9/30/2011
$7,500,000
Cara Therapeutics
9/30/2011
$7,000,000
SARCode Bioscience
7/18/2011
$44,000,000
MacroGenics
3/31/2011
$12,017,000
nCircle
3/31/2011
$1,001,100
VertiFlex
2/2/2011
$14,000,000
Calistoga Pharmaceuticals
12/31/2010
$5,719,000
Sutro Biopharma
11/17/2010
$36,500,000
Ceregene
11/11/2010
$11,500,000
aTyr Pharma
10/26/2010
$23,000,000
Pathwork Diagnostics
10/6/2010
$30,000,000
Taligen Therapeutics
8/23/2010
$10,000,000
Immune Design
7/26/2010
$32,000,000
Cara Therapeutics
7/21/2010
$15,000,000
Trevena
7/14/2010
$35,000,000
Calistoga Pharmaceuticals
6/30/2010
$40,000,000
Virobay
6/30/2010
$10,000,000
Sonexa Therapeutics
6/30/2010
$37,233,000
Nereus Pharmaceuticals
6/23/2010
$20,000,000
FoldRx Pharmaceuticals
6/15/2010
$29,000,000
Achaogen
4/7/2010
$56,000,000
Phenomix
3/31/2010
$5,955,800
Excaliard Pharmaceuticals
3/31/2010
$2,500,000
AcelRx Pharmaceuticals
12/31/2009
$14,814,000
Avid Radiopharmaceuticals
12/31/2009
$15,363,000
SARCode Bioscience
12/31/2009
$4,000,000
Xirrus
12/31/2009
$20,100,000
Metabolex
11/6/2009
$8,600,000
DiscoveRx
9/30/2009
$240,000
Chimerix
8/11/2009
$16,000,000
Auction Direct
7/28/2009
$12,000,000
Vaccsys
6/30/2009
$1,667,000
Trevena
6/30/2009
$11,000,000
Neothetics
6/30/2009
$10,000,000
SARCode Bioscience
6/30/2009
$3,486,000
Avid Radiopharmaceuticals
5/21/2009
$34,500,000
Taligen Therapeutics
5/12/2009
$26,000,000
Calistoga Pharmaceuticals
5/5/2009
$30,000,000
Sonexa Therapeutics
3/31/2009
$13,525,000
Excaliard Pharmaceuticals
3/31/2009
$3,983,000
Sutro Biopharma
3/30/2009
$15,000,000
Sanarus Medical
1/13/2009
$3,000,000
DiscoveRx
12/31/2008
$4,000,000
Arete Therapeutics
11/19/2008
$16,700,000
ChemoCentryx
10/2/2008
$50,000,000
MacroGenics
9/25/2008
$25,000,000
Cara Therapeutics
7/25/2008
$12,300,000
HDL Therapeutics
6/30/2008
$10,250,000
Sierra Surgical Technologies
6/30/2008
$14,501,100
Vaccsys
6/18/2008
$9,000,000
Esperion Therapeutics
5/1/2008
$22,750,000
Neothetics
3/31/2008
$10,000,000
Nanomix
3/31/2008
$2,000,100
AcelRx Pharmaceuticals
3/31/2008
$20,218,100
SCYNEXIS
3/24/2008
$13,500,000
Trevena
3/5/2008
$24,000,000
Taligen Therapeutics
2/1/2008
$65,000,000
Sonexa Therapeutics
1/31/2008
$30,000,000
Calistoga Pharmaceuticals
1/3/2008
$5,200,000
SARCode Bioscience
12/31/2007
$7,000,000
Excaliard Pharmaceuticals
12/31/2007
$15,499,900
Novelion Therapeutics
12/31/2007
$17,605,000
Virobay
12/31/2007
$8,000,000
Calistoga Pharmaceuticals
12/31/2007
$15,735,000
Fundamental Applied Biology
12/10/2007
$21,000,000
Carbylan Therapeutics
11/26/2007
$20,000,000
Aerie Pharmaceuticals
9/30/2007
$10,000,000
nCircle
9/30/2007
$15,962,000
Phenomix
9/30/2007
$27,499,600
Coapt Systems
9/30/2007
$1,236,000
Sierra Surgical Technologies
8/15/2007
$7,100,000
Nereus Pharmaceuticals
8/9/2007
$45,000,000
Agensys
7/12/2007
$41,300,000
nCircle
6/30/2007
$5,000,000
Nanomix
6/30/2007
$8,036,000
Virobay
6/30/2007
$5,000,000
Paracor Medical
6/28/2007
$44,350,000
Arete Therapeutics
5/23/2007
$13,300,000
ProLacta BioSciences
5/23/2007
$12,000,000
Xelerated
5/8/2007
$23,000,000
Portola Pharmaceuticals
5/7/2007
$70,000,000
SurgRx
4/20/2007
$20,000,000
Metabolex
4/19/2007
$32,000,000
Auction Direct
4/18/2007
$10,500,000
TransMedics
4/13/2007
$25,500,000
Neothetics
3/31/2007
$1,500,000
Intradigm
3/31/2007
$3,875,000
DiscoveRx
3/31/2007
$5,000,000
FoldRx Pharmaceuticals
3/31/2007
$32,251,300
Coapt Systems
3/29/2007
$22,600,000
Aerovance
3/27/2007
$32,000,000
ChemoCentryx
3/22/2007
$29,840,000
Intarcia Therapeutics
3/19/2007
$50,000,000
Phenomix
3/8/2007
$55,000,000
PneumRx
3/6/2007
$27,000,000
Calistoga Pharmaceuticals
3/6/2007
$21,000,000
Virobay
3/5/2007
$333,000
Chimerix
2/23/2007
$23,100,000
Sanarus Medical
2/20/2007
$15,000,000
Proacta
2/7/2007
$35,000,000
VertiFlex
1/22/2007
$20,000,000
Cara Therapeutics
11/28/2006
$19,000,000
Intradigm
11/21/2006
$16,000,000
Cerenis Therapeutics
11/13/2006
$53,500,000
ChemoCentryx
8/24/2006
$17,700,000
Ablynx
8/23/2006
$50,000,000
Kemia
8/23/2006
$31,000,000
Kmia
8/23/2006
$31,000,000
TorreyPines Therapeutics
6/30/2006
$6,364,000
Triple Point Medical
6/30/2006
$399,900
USGI Medical
6/30/2006
$21,060,000
Novelion Therapeutics
6/14/2006
$22,000,000
FoldRx Pharmaceuticals
5/31/2006
$43,000,000
U3 Pharma AG
5/23/2006
$34,000,000
MacroGenics
5/17/2006
$45,000,000
Aerovance
5/4/2006
$60,000,000
Syntonix Pharmaceuticals
3/31/2006
$2,000,000
NeurogesX
3/31/2006
$5,065,000
Alba Therapeutics
3/31/2006
$23,000,000
Nereus Pharmaceuticals
3/31/2006
$18,300,300
Phenomix
3/31/2006
$20,005,100
BrandMuscle
3/31/2006
$750,000
TransMedics
3/14/2006
$29,750,000
Aegis Semiconductor
3/8/2006
$8,000,000
Insulet
2/16/2006
$50,000,000
Netli
2/15/2006
$18,000,000
RedShift BioAnalytics
1/11/2006
$12,000,000
NeurogesX
12/1/2005
$20,000,000
Carbylan Therapeutics
11/30/2005
$7,900,000
Portola Pharmaceuticals
11/8/2005
$46,000,000
Aerie Pharmaceuticals
10/12/2005
$21,000,000
Aegis Semiconductor
9/30/2005
$2,855,000
Alba Therapeutics
8/22/2005
$30,000,000
PneumRx
6/30/2005
$2,199,900
Phenomix
5/24/2005
$40,000,000
Azelon Pharmaceuticals
5/18/2005
$42,500,000
Xelerated
4/20/2005
$17,000,000
Sanarus Medical
4/13/2005
$23,000,000
Plexxikon
3/31/2005
$7,500,000
Nanomix
3/4/2005
$16,000,000
Arete Therapeutics
2/21/2005
$15,000,000
Nereus Pharmaceuticals
1/4/2005
$42,600,000
MyNewPlace
12/21/2004
$24,000,000
Intarcia Therapeutics
12/1/2004
$50,000,000
Metabolex
11/30/2004
$44,000,000
Netli
11/8/2004
$8,000,000
Xelerated
10/5/2004
$10,000,000
Ceregene
8/4/2004
$32,000,000
Coapt Systems
5/27/2004
$12,000,000
Plexxikon
5/26/2004
$15,000,000
CPS
5/25/2004
$9,000,000
Ablynx
4/6/2004
$30,000,000
Kemia
3/29/2004
$33,500,000
Mempile
3/3/2004
$11,600,000
Insulet
3/2/2004
$35,500,000
NeurogesX
2/24/2004
$35,000,000
TransMedics
1/27/2004
$27,600,000
Cellomics
1/9/2004
$5,300,000
Native Networks
11/18/2003
$4,300,000
CoTherix
10/14/2003
$55,000,000
Phenomix
10/14/2003
$35,500,000
Renovis
8/11/2003
$45,000,000
Native Networks
7/14/2003
$11,500,000
Xelerated
7/14/2003
$12,500,000
Rigel Pharmaceuticals
6/27/2003
$46,000,000
Coapt Systems
2/7/2003
$12,000,000
Agensys
3/5/2002
$42,800,000

 

Investor Contacts

Title
Name
Email & Social
Managing Director
Peter Hudson
  Peter Hudson LinkedIn Profile  Peter Hudson Twitter Account  Peter Hudson News  Peter Hudson on Facebook
Managing Director
Daniel Janney
  Daniel Janney LinkedIn Profile  Daniel Janney Twitter Account  Daniel Janney News  Daniel Janney on Facebook
Managing Director
Robert More
  Robert More LinkedIn Profile  Robert More Twitter Account  Robert More News  Robert More on Facebook

 

Funds

Our database includes the following fund closing(s) for Alta Partners. If we are missing funds, please contact us.

Fund Description
Vintage Date
Fund Amount
Alta Partners NextGen Fund I
6/12/2018
$130,000,000
Alta Partners VIII
6/30/2006
$500,000,000

 

Portfolio Companies

Alta Partners has invested in the companies below, according to our database records. If we are missing a portfolio company, please let us know.

Tech Company
Ablynx
AcelRx Pharmaceuticals
Achaogen
Aegis Semiconductor
Aerie Pharmaceuticals
Aerovance
Agensys
AGTC
Alba Therapeutics
Allakos
Arete Therapeutics
aTyr Pharma
Auction Direct
Avid Radiopharmaceuticals
Azelon Pharmaceuticals
Be Biopharma
BetterVet
BrandMuscle
BridgeHealth
Calistoga Pharmaceuticals
Cara Therapeutics
Carbylan Therapeutics
Cellomics
Ceregene
Cerenis Therapeutics
ChemoCentryx
Chimerix
Coapt Systems
CoTherix
CPS
CuraSen Therapeutics
CymaBay Therapeutics
DEM BioPharma
DiscoveRx
DispatchHealth
Edgewood Oncology
eGenesis
Esperion Therapeutics
Everside Health
Excaliard Pharmaceuticals
FoldRx Pharmaceuticals
Free Market Health
Fundamental Applied Biology
Harbor Health
HDL Therapeutics
Immune Design
ImmuneID
Insulet
Intarcia Therapeutics
Intradigm
Kelonia Therapeutics
Kemia
Kite Pharma
Kmia
Lassen Therapeutics
Lumena Pharmaceuticals
MacroGenics
MBrace Therapeutics
Mempile
Metabolex
MyNewPlace
Nanomix
Native Networks
nCircle
Neothetics
Nereus Pharmaceuticals
Netli
NeurogesX
Novelion Therapeutics
Novome Biotechnologies
Paladina Health
Paracor Medical
Pathwork Diagnostics
PatientsLikeMe
Phenomix
Plexxikon
PneumRx
Portola Pharmaceuticals
Proacta
Progentos Therapeutics
ProLacta BioSciences
Reach Analytics
RedShift BioAnalytics
Renovis
Rigel Pharmaceuticals
Sanarus Medical
SARCode Bioscience
SCYNEXIS
Sierra Surgical Technologies
Sonexa Therapeutics
SurgRx
Sutro Biopharma
Syntonix Pharmaceuticals
Taligen Therapeutics
TorreyPines Therapeutics
Transcarent
TransMedics
Trevena
Triple Point Medical
Tyra Biosciences
U3 Pharma AG
USGI Medical
Vaccsys
VertiFlex
Vir Biotechnology
Virobay
Xelerated
Xirrus
Zafgen
ZS Pharma

 

 

 

 

Browse more venture capital investors:

Alta Life Sciences | Alta Semper

 

Share this article

 

About Our Venture Capital Investors Database

The venture capital investor data above is provided by VentureDeal.com, a leading provider of venture capital transaction data.

 

Additional Resources for Entrepreneurs

Lists of Venture Capital and Private Equity Firms

Franchise Opportunities

Contributors

Business Glossary

 

Copyright © 2001-2024. Gaebler Ventures. All rights reserved.